标题
Targeting CD22 in B-cell Malignancies: Current Status and Clinical Outlook
作者
关键词
Acute Lymphoblastic Leukemia, Overall Response Rate, Hairy Cell Leukemia, Dexrazoxane, Pegylated Liposomal Doxorubicin
出版物
BIODRUGS
Volume 27, Issue 4, Pages 293-304
出版商
Springer Nature
发表日期
2013-05-21
DOI
10.1007/s40259-013-0016-7
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- CD22 Antigen Is Broadly Expressed on Lung Cancer Cells and Is a Target for Antibody-Based Therapy
- (2012) J. M. Tuscano et al. CANCER RESEARCH
- Antibody–drug conjugates – a perfect synergy
- (2012) John R Adair et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Differences in drug approval processes of 3 regulatory agencies: a case study of gemtuzumab ozogamicin
- (2012) Tetsuya Tanimoto et al. INVESTIGATIONAL NEW DRUGS
- Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia
- (2012) Robert J. Kreitman et al. JOURNAL OF CLINICAL ONCOLOGY
- Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
- (2012) Hagop Kantarjian et al. LANCET ONCOLOGY
- Efficacy of a CD22-targeted antibody-saporin conjugate in a xenograft model of precursor-B cell acute lymphoblastic leukemia
- (2012) Jason Kato et al. LEUKEMIA RESEARCH
- Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy
- (2012) H. Wei et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin’s lymphoma
- (2012) Jason Kato et al. OncoImmunology
- Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma
- (2011) I. N. M. Micallef et al. BLOOD
- Treatment of Hematologic Malignancies with Immunotoxins and Antibody-Drug Conjugates
- (2011) D. J. FitzGerald et al. CANCER RESEARCH
- Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin
- (2011) A. D. Ricart CLINICAL CANCER RESEARCH
- Immunotoxins with decreased immunogenicity and improved activity
- (2011) Ira Pastan et al. LEUKEMIA & LYMPHOMA
- Targeting B lymphoma with nanoparticles bearing glycan ligands of CD22
- (2011) Weihsu C. Chen et al. LEUKEMIA & LYMPHOMA
- Epratuzumab-SN-38: A New Antibody-Drug Conjugate for the Therapy of Hematologic Malignancies
- (2011) R. M. Sharkey et al. MOLECULAR CANCER THERAPEUTICS
- In vivo targeting of B-cell lymphoma with glycan ligands of CD22
- (2010) W. C. Chen et al. BLOOD
- Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP
- (2010) John F. DiJoseph et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial
- (2010) A. S. Wayne et al. CLINICAL CANCER RESEARCH
- Efficacy, Biodistribution, and Pharmacokinetics of CD22-Targeted Pegylated Liposomal Doxorubicin in a B-cell Non-Hodgkin's Lymphoma Xenograft Mouse Model
- (2010) J. M. Tuscano et al. CLINICAL CANCER RESEARCH
- Investigational antibody-drug conjugates for hematological malignancies
- (2010) Andrew G Polson et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Oversight of Fast-Track Drug Approval by FDA Stuck in Low Gear, Critics Say
- (2010) Mike Mitka JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- High Rates of Durable Responses With Anti-CD22 Fractionated Radioimmunotherapy: Results of a Multicenter, Phase I/II Study in Non-Hodgkin's Lymphoma
- (2010) Franck Morschhauser et al. JOURNAL OF CLINICAL ONCOLOGY
- Vitamin D Insufficiency and Prognosis in Non-Hodgkin's Lymphoma
- (2010) Matthew T. Drake et al. JOURNAL OF CLINICAL ONCOLOGY
- CD22 Is a Recycling Receptor That Can Shuttle Cargo between the Cell Surface and Endosomal Compartments of B Cells
- (2010) M. K. O'Reilly et al. JOURNAL OF IMMUNOLOGY
- FDA Increases Focus on Postmarketing Studies
- (2010) M. Goozner JNCI-Journal of the National Cancer Institute
- Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma
- (2010) A G Polson et al. LEUKEMIA
- Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma
- (2009) Vincent Ribrag et al. CANCER
- Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts
- (2009) Robert T. O’Donnell et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD)
- (2009) Robert T. O’Donnell et al. INVESTIGATIONAL NEW DRUGS
- Statin Use and Prognosis in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in the Rituximab Era
- (2009) Grzegorz S. Nowakowski et al. JOURNAL OF CLINICAL ONCOLOGY
- Developmental Acquisition of the Lyn-CD22-SHP-1 Inhibitory Pathway Promotes B Cell Tolerance
- (2009) A. J. Gross et al. JOURNAL OF IMMUNOLOGY
- Durable complete responses from therapy with combined epratuzumab and rituximab
- (2008) John P. Leonard et al. CANCER
- Therapy of Advanced B-Lymphoma Xenografts with a Combination of 90Y-anti-CD22 IgG (Epratuzumab) and Unlabeled Anti-CD20 IgG (Veltuzumab)
- (2008) M. J. Mattes et al. CLINICAL CANCER RESEARCH
- CD22: an inhibitory enigma
- (2008) Jennifer A. Walker et al. IMMUNOLOGY
- Chemoimmunotherapy Reinduction With Epratuzumab in Children With Acute Lymphoblastic Leukemia in Marrow Relapse: A Children's Oncology Group Pilot Study
- (2008) Elizabeth A. Raetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Reinduction Platform for Children With First Marrow Relapse of Acute Lymphoblastic Leukemia: A Children's Oncology Group Study
- (2008) Elizabeth A. Raetz et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now